Caris Life Sciences Inc (CAI)

$20.20 +0.41 (2.07%)
Market Cap 5.59B
Revenue (ttm) 812.03M
Net Income (ttm) -68.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 170.83
Profit Margin -8.39%
Debt to Equity Ratio 0.66
Volume 830,300
Avg Vol 2,333,522
Day's Range N/A - N/A
Shares Out 282.58M
Stochastic %K 33%
Beta N/A
Analysts Strong Sell
Price Target $30.46

Company Profile

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions;...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 771 8946
Fax: 866 479 4925
Address:
750 West John Carpenter Freeway, Suite 800, Irving, United States
Damian23
Damian23 Apr. 15 at 10:24 AM
$TEM Im bullish on both but don't sleep on $CAI , I don't really know why the divergence in followers between these 2, although TEM is more diversified, CAI is best in class as well. I hope they both double by end of year.
2 · Reply
CromieAds
CromieAds Apr. 14 at 10:04 PM
$CAI will be a triple digit stock once the multi early detection cancer test progresses. It’s the best available today and available soon (first half of 2026)
0 · Reply
Ron12341
Ron12341 Apr. 14 at 2:05 AM
$CAI waiting for this to take off… Good analyst coverage lately
1 · Reply
notreload_ai
notreload_ai Apr. 13 at 4:04 PM
Canaccord says $BHVN is undervalued and could rise on epilepsy trial results. Jefferies likes $CAI and $VCYT , citing strong growth in cancer diagnostics and solid finances. https://notreload.xyz/xy/analysts-turn-bullish-on-biohaven-caris-and-veracyte/
0 · Reply
prismmarketview
prismmarketview Apr. 9 at 12:08 PM
$CAI Caris Life Sciences rolled out a multimodal AI signature for NSCLC that tells you when to add chemo to IO—and when to avoid it. Same WES/WTS data backbone as their other Caris AI Insights, but now aimed directly at chemo harm vs benefit. @carisls #Chemotherapy #Oncology https://prismmarketview.com/caris-launches-ai-tool-to-show-when-chemo-helps-or-hurts-lung-cancer-patients/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 8 at 4:12 PM
$CAI RSI: 57.49, MACD: -0.2924 Vol: 0.74, MA20: 18.53, MA50: 20.03 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CromieAds
CromieAds Apr. 2 at 7:29 PM
$CAI https://www.prnewswire.com/news-releases/caris-life-sciences-announces-launch-of-caris-chromoseq-the-worlds-first-whole-genome-and-whole-transcriptome-tumor-profiling-assay-for-myeloid-malignancies-302732465.html
0 · Reply
stockpicker63
stockpicker63 Apr. 1 at 5:34 PM
📈 Technical Confirmation: Trend & Momentum: The stock is recovering strongly after a brief consolidation in March. The MACD has just made a bullish crossover, and the RSI of 57.3 indicates there is still significant room for growth before the stock becomes "overbought." Moving Averages: The stock is trading above its 5-day ($19.16) and 50-day ($18.78) moving averages. Only the 200-day average ($19.31) is acting as slight resistance; a breakout above this level could trigger a new wave of institutional buying. Pivot Points: Resistance: $19.31 (200-MA), $22.21 (Technical Target). Support: $18.20 (Pivot), $17.50 (Solid Bottom). Strategic Note (Update 04-01-2026): $CAI currently displays one of the strongest "AI-diagnostics" profiles in the market. The combination of a very high SST-score (9/10) and recent support from GS .makes this a top candidate for a swing trade. Historically, the stock tends to trend upward for 3 to 5 days following a positive analyst initiation. Verdict: STRONG BUY
0 · Reply
Ron12341
Ron12341 Apr. 1 at 1:52 PM
$CAI GS with a nice $27 price target
0 · Reply
CromieAds
CromieAds Apr. 1 at 1:46 PM
$CAI $EXAS $GH $GRAL
0 · Reply
Latest News on CAI
Caris Life Sciences Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 2 months ago

Caris Life Sciences Earnings Call Transcript: Q4 2025

Caris Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 3 months ago

Caris Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Caris Life Sciences Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 6 months ago

Caris Life Sciences Earnings Call Transcript: Q3 2025

Caris Life Sciences Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 9 months ago

Caris Life Sciences Earnings Call Transcript: Q2 2025

Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering

May 23, 2025, 5:54 PM EDT - 1 year ago

Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering

Caris Life Sciences discloses rise in revenue in US IPO filing

May 23, 2025, 5:12 PM EDT - 1 year ago

Caris Life Sciences discloses rise in revenue in US IPO filing

Oncology precision medicine platform Caris Life Sciences files for an estimated $300 million IPO

May 23, 2025, 4:22 PM EDT - 1 year ago

Oncology precision medicine platform Caris Life Sciences files for an estimated $300 million IPO

Caris Life Sciences IPO Registration Document (S-1)

May 23, 2025, 3:27 PM EDT - 1 year ago

Caris Life Sciences IPO Registration Document (S-1)

Damian23
Damian23 Apr. 15 at 10:24 AM
$TEM Im bullish on both but don't sleep on $CAI , I don't really know why the divergence in followers between these 2, although TEM is more diversified, CAI is best in class as well. I hope they both double by end of year.
2 · Reply
CromieAds
CromieAds Apr. 14 at 10:04 PM
$CAI will be a triple digit stock once the multi early detection cancer test progresses. It’s the best available today and available soon (first half of 2026)
0 · Reply
Ron12341
Ron12341 Apr. 14 at 2:05 AM
$CAI waiting for this to take off… Good analyst coverage lately
1 · Reply
notreload_ai
notreload_ai Apr. 13 at 4:04 PM
Canaccord says $BHVN is undervalued and could rise on epilepsy trial results. Jefferies likes $CAI and $VCYT , citing strong growth in cancer diagnostics and solid finances. https://notreload.xyz/xy/analysts-turn-bullish-on-biohaven-caris-and-veracyte/
0 · Reply
prismmarketview
prismmarketview Apr. 9 at 12:08 PM
$CAI Caris Life Sciences rolled out a multimodal AI signature for NSCLC that tells you when to add chemo to IO—and when to avoid it. Same WES/WTS data backbone as their other Caris AI Insights, but now aimed directly at chemo harm vs benefit. @carisls #Chemotherapy #Oncology https://prismmarketview.com/caris-launches-ai-tool-to-show-when-chemo-helps-or-hurts-lung-cancer-patients/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 8 at 4:12 PM
$CAI RSI: 57.49, MACD: -0.2924 Vol: 0.74, MA20: 18.53, MA50: 20.03 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CromieAds
CromieAds Apr. 2 at 7:29 PM
$CAI https://www.prnewswire.com/news-releases/caris-life-sciences-announces-launch-of-caris-chromoseq-the-worlds-first-whole-genome-and-whole-transcriptome-tumor-profiling-assay-for-myeloid-malignancies-302732465.html
0 · Reply
stockpicker63
stockpicker63 Apr. 1 at 5:34 PM
📈 Technical Confirmation: Trend & Momentum: The stock is recovering strongly after a brief consolidation in March. The MACD has just made a bullish crossover, and the RSI of 57.3 indicates there is still significant room for growth before the stock becomes "overbought." Moving Averages: The stock is trading above its 5-day ($19.16) and 50-day ($18.78) moving averages. Only the 200-day average ($19.31) is acting as slight resistance; a breakout above this level could trigger a new wave of institutional buying. Pivot Points: Resistance: $19.31 (200-MA), $22.21 (Technical Target). Support: $18.20 (Pivot), $17.50 (Solid Bottom). Strategic Note (Update 04-01-2026): $CAI currently displays one of the strongest "AI-diagnostics" profiles in the market. The combination of a very high SST-score (9/10) and recent support from GS .makes this a top candidate for a swing trade. Historically, the stock tends to trend upward for 3 to 5 days following a positive analyst initiation. Verdict: STRONG BUY
0 · Reply
Ron12341
Ron12341 Apr. 1 at 1:52 PM
$CAI GS with a nice $27 price target
0 · Reply
CromieAds
CromieAds Apr. 1 at 1:46 PM
$CAI $EXAS $GH $GRAL
0 · Reply
CromieAds
CromieAds Mar. 31 at 11:44 PM
$CAI should run up nicely tomorrow. This is big news!… https://www.prnewswire.com/news-releases/caris-life-sciences-finalizes-achieve-1-study-results-reinforcing-the-superior-sensitivity-and-specificity-of-caris-detect-302730659.html $EXAS $GH $GRAL
1 · Reply
ggabel7
ggabel7 Mar. 31 at 8:00 PM
😜 he he he what a gift here $TPET orange 🍊 telling the rest of the world to go get they own oil and you are selling scare thinking the middle east oil will come back the next day that’s funny .russia only produces 7% and oil went 150 barrel. now we have 20% off and you’re scared i’m locked and loading long TPET. 19 millions cash with more news on the way good luck $BFRG $BURU $CAI $BYND
0 · Reply
Damian23
Damian23 Mar. 29 at 1:47 PM
$CAI Anyone knows why Guardant health is trading at double valuation? Almost same revenue, CAI is closer to profitability, similar efficacy although GH uses liquid biopsy.Thanks
0 · Reply
jmash
jmash Mar. 27 at 6:54 PM
$CAI yikes. Probably people selling to maintain margin requirements but still…
0 · Reply
Damian23
Damian23 Mar. 27 at 6:30 PM
$CAI we are expected a readout by the end of the month?I dont like the price action today, maybe someone knows somenthing? or just market volatility?
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 26 at 12:33 PM
$CAI - Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer
0 · Reply
jmash
jmash Mar. 24 at 10:10 AM
$CAI looks like it may have found the bottom
1 · Reply
appayip
appayip Mar. 19 at 3:03 PM
$CAI i hope they wait to release good news, till this shit war ends.
0 · Reply
Dietl
Dietl Mar. 16 at 7:36 PM
$CAI $50
1 · Reply
appayip
appayip Mar. 13 at 3:12 PM
$CAI what are your long term price targets?
1 · Reply
appayip
appayip Mar. 12 at 2:41 PM
$CAI buy order filled. can't wait to hear more results of their early detection test. this company is great in the long run too actually, if i am not mistaken, they makes agreement with big pharma, when they find a medicine by using data of Caris, they will give caris percentage from their revenue of that medicine.
0 · Reply
microeone
microeone Mar. 10 at 5:04 PM
$CAI the blinded validation study results are likely to be released by the end of this month for Caris detect… how is everyone feeling on the probability of the sensitivity and specificity to remain intact? Management sounded very optimistic and bullish on the last earnings call. Big moment because Cari’s detect commercial launch was not factored into 2026 revenue.
0 · Reply